This study investigates whether administering reduced dose is non-inferior to standard dose radiotherapy in terms of 3-year locoregional relapse-free survival (LRRFS) rate for stage I nasopharyngeal carcinoma patients who are sensitive to radiotherapy.
Age 18-70, regardless of sex.
Patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma, type of WHO II or III, clinical stage I (according to the 9th American Joint Committee on Cancer[AJCC] edition).
Patients with CR according to RECIST and EBV DNA undetectable after received 50.88Gy radiation.
ECOG (Eastern Cooperative Oncology Group) score: 0-1.
Histologically confirmed keratinizing squamous cell carcinoma (WHO I).
Patients with PR/SD/PD according to RECIST and/or EBV DNA detectable after received 50.88Gy radiation.
Receiving radiotherapy or chemotherapy or targeted therapy previously.
Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy on the fetus or infant.
Hai-Qiang Mai,MD,PhD
Lead sponsor
Sun Yat-sen University
Sponsor institution